Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey

Crispino, Federica; Brinch, Daniele; Carrozza, Lucio; Cappello, Maria

doi:10.1093/ibd/izab133

Cited by 10 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, half of patients with IBD wished to be vaccinated against SARS-CoV-2, and this rate was similar to that reported in the French general population [1]. In Italy, a survey measured the acceptance of anti-SARS-CoV-2 vaccination in an IBD population, and the proportion of patients willing to be vaccinated against SARS-CoV-2 was 53.6%, which is similar to our cohort [2]. The high rate of vaccine acceptance in Europe could be explained, at least in part, by the recommendations of the European Crohn's and Colitis Organisation (ECCO) task force to use the mRNA (messenger ribonucleic acid) vaccine to vaccinate IBD patients, published in February 2021 [3].…”

Section: Replysupporting

confidence: 88%

COVID-19 Vaccination in Patients with Inflammatory Bowel Disease: A Survey from China

2021

View full text Add to dashboard Cite

Section: Replysupporting

confidence: 88%

COVID-19 Vaccination in Patients with Inflammatory Bowel Disease: A Survey from China

2021

View full text Add to dashboard Cite

“…A pooled estimate of 63 studies 11 , 12 , 14 , 25 , 29 , 31 , 32 , 36 , 37 , 39 – 43 , 49 – 54 , 58 , 59 , 61 , 66 – 69 , 72 , 75 , 77 – 82 , 85 , 86 , 88 – 96 , 98 , 99 , 102 – 104 , 106 indicated an overall prevalence rate of 6.10% (95% CI 3.15–9.04%) of COVID-19 in patients with any IBD. Heterogeneity was very high (I 2 : 100%); hence a random effect model was used.…”

Section: Resultsmentioning

confidence: 99%

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Abdulla

Mohammed

AlQamish

et al. 2022

Sci Rep

View full text Add to dashboard Cite

There is conflicting evidence concerning the effect of inflammatory bowel disease (IBD) on COVID-19 incidence and outcome. Hence, we aimed to evaluate the published evidence through a systematic review process and perform a meta-analysis to assess the association between IBD and COVID-19. A compressive literature search was performed in PubMed/Medline, Scopus, Embase, and Cochrane Library from inception to July 2021. A snowball search in Google, Google Scholar, Research Gate, and MedRxiv; and bibliographic research were also performed to identify any other relevant articles. Quantitative observational studies such as cohort, cross-sectional, and case–control studies that assessed the incidence, risk, and outcomes of COVID-19 among the adult IBD patients published in the English language, were considered for this review. The incidence and risk of COVID-19, COVID-19 hospitalization, the severity of COVID-19, and mortality were considered as the outcomes of interest. The Joanna Briggs Institute critical appraisal checklist was used for quality assessment. A subgroup and sensitivity analysis were performed to explore the heterogeneity and robustness of the results, respectively. A total of 86 studies out of 2828 non-duplicate records were considered for this meta-analysis. The studies were single or multicentric internationally from settings such as IBD centres, medical colleges, hospitals, or from the general public. Most of the studies were observed to be of good quality with an acceptable risk of bias. The pooled prevalence of COVID-19, COVID-19 hospitalization, severe COVID-19, and mortality in the IBD population were 6.10%, 10.63%, 40.43%, and 1.94%, respectively. IBD was not significantly (p > 0.05) associated with the risk of COVID-19, COVID-19 hospitalization, severe COVID-19, and mortality. In contrast, ulcerative colitis was significantly associated with a higher risk of COVID-19 (OR 1.37; p = 0.01), COVID-19 hospitalization (OR 1.28; p < 0.00001), and severe COVID-19 (OR 2.45; p < 0.0007). Crohn’s disease was significantly associated with a lesser risk of severe COVID-19 (OR 0.48; p = 0.02). Type of IBD was a potential factor that might have contributed to the higher level of heterogeneity. There was a significant association between ulcerative colitis and increased risk of COVID-19, COVID-19 hospitalization, and severe COVID-19 infection. This association was not observed in patients with Crohns' disease or in those diagnosed non-specifically as IBD.

show abstract

“…This is one of the important causes of vaccine hesitancy in patients with IBD. A survey in Italy revealed fear of negative impact on the course of IBD was seen in 52% of respondents [51] . To address this, we found gastrointestinal related adverse effects were also low in incidence and a flare of underlying disease activity in IBD following vaccination was seen in extremely small numbers.…”

Section: Discussionmentioning

confidence: 99%

Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis

James

Jena

Bharath

et al. 2022

Digestive and Liver Disease

View full text Add to dashboard Cite

Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey

Cited by 10 publications

References 2 publications

COVID-19 Vaccination in Patients with Inflammatory Bowel Disease: A Survey from China

COVID-19 Vaccination in Patients with Inflammatory Bowel Disease: A Survey from China

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis

Contact Info

Product

Resources

About